



Please type a plus sign (+) inside this box → **+**

Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/549,506 (371 of PCT/DK04/00193)
		Filing Date	371(c) date: July 7, 2006
		First Named Inventor	K.V. Andersen
		Group Art Unit	
		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	0272us310

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<ul style="list-style-type: none"> • Form PTO/SB/08A-B (6 pp.)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	<ul style="list-style-type: none"> • 66 cited references (ref. Nos. 17-82)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	<ul style="list-style-type: none"> • Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Joanne R. Petithory	Maxygen, Inc.	Reg. No. 42,995
Signature			
Date	July 10, 2006		

Certificate of Mailing under 37 C.F.R. §1.8

I hereby certify that this is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to:
Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450, Mail Stop: Amendment on this date:

Typed or Printed Name: Ann Massey

Date: 11 July 2006

Signature: Ann Massey

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited as first-class mail addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, Mail-Stop: Amendment

On: 11 July 2006
By: Ann Massey
Ann Massey

Attorney Docket No: 0272us310

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ANDERSEN, Kim Vilbour, *et al.*

Examiner:

Application No.: 10/549,506

(371 of PCT/DK04/00193 filed March 22, 2004)

Art Unit:

371(c) date: July 7, 2006

**INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR § 1.97 AND § 1.98**

For: FVII OR FVIIA VARIANTS

Mail-Stop: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached form PTO/SB/08A-B are being called to the attention of the Examiner. Copies of cited references numbered 17- 82 are enclosed. Since the international application was filed after June 30, 2003, copies of the cited US patents and US published applications (references 1-16) are not provided herein, pursuant to MPEP § 609 III A(2).

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


ANDERSEN, Kim Vilbour, *et al.*
Application No.: 10/549,506 (371 of PCT/DK04/00193)
Information Disclosure Statement
page 2 of 2

Attorney Docket No.: 0272us310

It is believed that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date: July 10, 2006



Joanne R. Petithory, Ph.D.
Reg. No. 42,995

Maxygen, Inc.
Intellectual Property Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446

Customer No. 30560



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

		Complete if Known	
Application Number	10/549,506 (371 of PCT/DK04/00193)		
International Application Filing Date	March 22, 2004		
371(c) Date	July 7, 2006		
First Named Inventor	ANDERSEN, Kim Vilbour		
Group Art Unit			
Examiner Name			
Attorney Docket Number	0272us310		

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM/DD/YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	4,784,950		Hagen <i>et al.</i>	11/15/1998	
	2	4,904,584		Shaw	02/27/1990	
	3	5,041,376		Gething <i>et al.</i>	08/20/1991	
	4	5,180,583		Hedner	01/19/1993	
	5	5,225,537		Foster	07/06/1993	
	6	5,288,629		Berkner	02/22/1994	
	7	5,460,950		Barr <i>et al.</i>	10/24/1995	
	8	5,580,560		Nicolaisen <i>et al.</i>	12/03/1996	
	9	5,648,254		Mulvihill <i>et al.</i>	07/15/1997	
	10	5,824,634		Merchant	10/20/1998	
	11	5,861,374		Berkner <i>et al.</i>	01/19/1999	
	12	5,891,843		Turecek <i>et al.</i>	04/06/1999	
	13	5,965,425		Barr <i>et al.</i>	10/12/1999	
	14	5,986,079		Barr <i>et al.</i>	11/16/1999	
	15	6,013,620		Turecek <i>et al.</i>	01/11/2000	
	16	6,017,882		Nelsestuen	01/25/2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM/DD/YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	17	EP	0 370 205	A2	Kyowa Hakko Kogyo Co., Ltd.	05/30/1990		
	18	EP	0 512 011	B1	Immuno Aktiengesellschaft	11/11/1992		
	19	WO	88/10295	A1	Novo Industri A/S	12/29/1988		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

JUL 20 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


(use as many sheets as necessary)

Complete if Known	
Application Number	10/549,506 (371 of PCT/DK04/00193)
International Application Filing Date	March 22, 2004
371(c) Date	July 7, 2006
First Named Inventor	ANDERSEN, Kim Vilbour
Group Art Unit	
Examiner Name	
Attorney Docket Number	0272us310

20	WO	91/11514	A1	ZymoGenetics, Inc.	08/08/1991		
21	WO	92/15686	A1	ZymoGenetics, Inc.	09/17/1992		
22	WO	94/27631	A1	ZymoGenetics, Inc.	12/08/1994		
23	WO	96/00577	A1	COR Therapeutics, Inc.	01/11/1996		
24	WO	98/32466	A1	Polymasc Pharmaceuticals Plc	07/30/1998		
25	WO	98/35026	A1	Novo Nordisk A/S	08/13/1998		
26	WO	99/03498	A1	Novo Nordisk A/S	01/28/1999		
27	WO	99/03887	A1	Bolder Biotechnology, Inc.	01/28/1999		
28	WO	99/20767	A1	Regents of the University of Minnesota	04/29/1999		
29	WO	99/66031	A2	Baxter Aktiengesellschaft	12/23/1999		
30	WO	00/26230	A1	Novo Nordisk A/S	05/11/2000		
31	WO	00/26354	A1	Novo Nordisk A/S	05/11/2000		
32	WO	00/28065	A1	Novo Nordisk A/S	05/18/2000		
33	WO	00/54787	A1	The Children's Hospital of Philadelphia	09/21/2000		
34	WO	00/66753	A2	Regents of the University of Minnesota	11/09/2000		
35	WO	01/58935	A2	Maxygen ApS	08/16/2001		
36	WO	01/83725	A1	Novo Nordisk A/S	11/08/2001		
37	WO	02/077218	A1	Novo Nordisk A/S	10/03/2002		
38	WO	02/22776	A2	Novo Nordisk A/S	03/21/2002		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number		10/549,506 (371 of PCT/DK04/00193)	
		International Application Filing Date		March 22, 2004	
		371(c) Date		July 7, 2006	
		First Named Inventor		ANDERSEN, Kim Vilbour	
		Group Art Unit			
		Examiner Name			
		Attorney Docket Number		0272us310	


	39	WO	02/38162	A1	Scripps Research Institute	05/16/2002		
	40	WO	03/027147	A2	Novo Nordisk A/S	04/03/2003		
	41	WO	03/037932	A2	Novo Nordisk A/S	05/08/2003		
	42	WO	03/055512	A1	Novo Nordisk A/S	07/10/2003		
	43	WO	03/093465	A1	Maxygen ApS	11/13/2003		
	44	WO	2004/029091	A2	Maxygen ApS	04/08/2004		
	45	WO	2004/083361	A2	Maxygen Holdings Ltd.	09/30/2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	46	Bharadwaj, D., <i>et al.</i> , "Factor VII Central—A Novel Mutation in the Catalytic Domain that Reduces Tissue Factor Binding, Impairs Activation by Factor XA, and Abolishes Amidolytic and Coagulant Activity," <i>J. Biological Chemistry</i> 271(48):30685-30691 (1996)	
	47	Bjoern, S., <i>et al.</i> , "Human Plasma and Recombinant Factor VII – Characterization of O-Glycosylations at Serine Residues 52 and 60 and Effects of Site-Directed Mutagenesis of Serine 52 to Alanine," <i>J. Biological Chemistry</i> 266(17):11051-11057 (1991)	
	48	Chang, J-Y., <i>et al.</i> , "Replacing the First Epidermal Growth Factor-like Domain of Factor IX with That of Factor VII Enhances Activity In Vitro and in Canine Hemophilia B," <i>J. Clin. Invest.</i> 100(4):886-892 (1997)	
	49	Chang, Y-J., <i>et al.</i> , "Engineered Recombinant Factor VII Q ²¹⁷ Variants with Altered Inhibitor Specificities," <i>Biochemistry</i> 38:10940-10948 (1999)	
	50	Cheung, W.F. <i>et al.</i> , "Localization of an Epitope of Calcium-Dependent Monoclonal Antibody to the N-Terminal Region of the Gla Domain of Human Factor VII", <i>Thrombosis Research</i> , 79(2):199-206 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO		Complete if Known	
		Application Number	10/549,506 (371 of PCT/DK04/00193)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		International Application Filing Date	March 22, 2004
(use as many sheets as necessary)		371(c) Date	July 7, 2006
		First Named Inventor	ANDERSEN, Kim Vilbour
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	0272us310

51	Cheung, W.F. <i>et al.</i> , "Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX", <i>Thrombosis Research</i> , 80(5):419-427 (1995).
52	Database EMBL, "Gallus gallus anticoagulant protein C precursor (PROC) mRNA, complete cds", Database Accession No. AF465270, Feb. 2 2003.
53	Database UNIPROT, "Coagulation factor VII (EC 3.4.21.21) (Serum prothrombin conversion accelerator)", Database Accession No. P22457, Aug. 1 1991.
54	Dickinson, C.D., <i>et al.</i> , "Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa," <i>Proc. Natl. Acad. Sci. USA</i> 93:14379-14384 (1996).
55	Dickinson, C.D., <i>et al.</i> , "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," <i>J. Biological Chemistry</i> 272(32):19875-19879 (1997).
56	Dickinson, C. D. <i>et al.</i> , "Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite Of Factor VIIa", <i>J. Mol. Biol.</i> 277:959-971 (1998).
57	Hedner, U. "NovoSeven as a universal haemostatic agent." <i>Blood Coagul. Fibrinolysis</i> 11 Suppl 1:S107-S111 (2000).
58	Higashi, S. <i>et al.</i> "Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity," <i>J. Biol. Chem.</i> 271(43):26569-74 (1996).
59	Huang, Q., <i>et al.</i> , "Substrate Recognition by Tissue Factor-Factor VIIa – Evidence for Interaction of Residues Lys ¹⁶⁵ and Lys ¹⁶⁶ of Tissue Factor with the 4-Carboxyglutamate-Rich Domain of Factor X," <i>J. Biological Chemistry</i> 271(36):21752-21757 (1996).
60	Iino, M., <i>et al.</i> , "Functional Consequences of Mutations in Ser-52 and Ser-60 in Human Blood Coagulation Factor VII," <i>Archives Biochem. Biophys.</i> 352(2):182-192 (1998).
61	Iakhiaev, A. <i>et al.</i> "The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor", <i>Thromb. Haemost.</i> 85(3):458-463 (2001).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Substitute for form 1449A-B/PTO		Complete if Known	
		Application Number	10/549,506 (371 of PCT/DK04/00193)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		International Application Filing Date	March 22, 2004
(use as many sheets as necessary)		371(c) Date	July 7, 2006
		First Named Inventor	ANDERSEN, Kim Vilbour
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	0272us310

	62	Jin, J., <i>et al.</i> , "Factor VIIa's First Epidermal Growth Factor-like Domain's Role in Catalytic Activity," <i>Biochemistry</i> 38:1185-1192 (1999).	
	63	Jin, J. <i>et al.</i> , "Four Loops of the Catalytic Domain of Factor VIIa Mediate the Effect of the First EGF-like Domain Substitution on Factor VIIa Catalytic Activity", <i>J. Mol. Biol.</i> 307:1503-1517 (2001).	
	64	Kelly, C.R., <i>et al.</i> , "Ca ²⁺ Binding to the First Epidermal Growth Factor Module of Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function," <i>J. Biological Chemistry</i> 272(28):17467-17472 (1997)	
	65	Kemball-Cook, G., <i>et al.</i> , "Coagulation Factor VII Gln ¹⁰⁰ Arg—Amino Acid Substitution at the Epidermal Growth Factor 2-Protease Domain Interface Results in Severely Reduced Tissue Factor Binding and Procoagulant Function," <i>J. Biological Chemistry</i> 273(14):8516-8521 (1998).	
	66	Leonard, B.J.N., <i>et al.</i> , "Activation and Active Site Occupation Alter Conformation in the Region of the First Epidermal Growth Factor-like Domain of Human Factor VII," <i>J. Biological Chemistry</i> 275(45):34894-34900 (2000).	
	67	Mayer, S.A. "Ultra-early hemostatic therapy for intracerebral hemorrhage," <i>Stroke</i> 34(1):224-229 (2003).	
	68	Nelsetuen, G.L. <i>et al.</i> "Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction," <i>J. Biol. Chem.</i> 276(43):39825-39831 (2001).	
	69	Neuenschwander, P.F. <i>et al.</i> , "Alteration of the Substrate and Inhibitor Specificities of Blood Coagulation Factor VIIa: Importance of Amino Acid Residue K192", <i>Biochemistry</i> 34:8701-8707 (1995).	
	70	Persson, E., <i>et al.</i> , "Site-directed mutagenesis but not γ -carboxylation of Glu-35 in factor VIIa affects the association with tissue factor," <i>FEBS Letters</i> 385:241-243 (1996).	
	71	Persson, E., "Characterization of the interaction between the light chain of factor VIIa and tissue factor," <i>FEBS Letters</i> 413:359-363 (1997).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

		Complete if Known
Application Number		10/549,506 (371 of PCT/DK04/00193)
International Application Filing Date		March 22, 2004
371(c) Date		July 7, 2006
First Named Inventor		ANDERSEN, Kim Vilbour
Group Art Unit		
Examiner Name		
Attorney Docket Number		0272us310

72	Persson, E., <i>et al.</i> , "Ca ²⁺ Binding to the First Epidermal Growth Factor-like Domain of Factor VIIa Increases Amidolytic Activity and Tissue Factor Affinity," <i>J. Biological Chemistry</i> 272(32):19919-19924 (1997).
73	Petersen, L.C., <i>et al.</i> , "Binding of Zn ²⁺ to a Ca ²⁺ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor," <i>Protein Science</i> 9:859-866 (2000).
74	Petrovan, R.J., <i>et al.</i> , "Role of Residue Phe ²²⁵ in the Cofactor-Mediated, Allosteric Regulation of the Serine Protease Coagulation Factor VIIa," <i>Biochemistry</i> 39:14457-14463 (2000).
75	Petrovan, R.J., <i>et al.</i> , "Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa" <i>J. Biol. Chem.</i> 276(9):6616-6620 (2001).
76	Ruf, W., <i>et al.</i> , "Importance of Factor VIIa Gla-Domain Residue Arg-36 for Recognition of the Macromolecular Substrate Factor X Gla-Domain," <i>Biochemistry</i> 38:1957-1966 (1999)
77	Shah, A.M., <i>et al.</i> , "Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII," <i>Proc. Natl. Acad. Sci. USA</i> 95:4229-4234 (1998).
78	Shobe, J., <i>et al.</i> , "Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex is Independent of Scissile Bond Docking," <i>J. Biological Chemistry</i> 274(34):24171-24175 (1999).
79	Shobe, J., <i>et al.</i> , "Regulation of the Catalytic Function of Coagulation Factor VIIa by a Conformational Linkage of Surface Residue Glu 154 to the Active Site," <i>Biochemistry</i> 38:2745-2751 (1999).
80	Sorensen, B.B. <i>et al.</i> "Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor," <i>J. Biol. Chem.</i> 272(18):11863-11868 (1997).
81	Sridhara S. <i>et al.</i> "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor," <i>Am. J. Hematol.</i> 53(2):66-71 (1996).
82	Zhang, E. <i>et al.</i> , "Structure of Extracellular Tissue Factor Complexed with Factor VIIa Inhibited with a BPTI Mutant," <i>J. Mol. Biol.</i> 285(5):2089-2104 (1999).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.